New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2012
12:12 EDTXOM, SNX, TYC, PNR, BMY, AMLN, BNNY, CVX, RDS.A, ALIMOn The Fly: Mid-Day Wrap
Stocks on Wall Street are lower at mid-day, after a report on durable goods orders in February fell short of expectations. After a meandering start to the session the averages have found their direction and it is lower. Each of the major equity indices is firmly in negative territory and at session lows. The market began the session mixed and seemed unaffected by the generally in-line durable goods orders report. The market also ignored the weekly DOE energy inventory reports until the averages broke out of their tight range and moved to the downside, gaining negative momentum as the day progresses... ECONOMIC EVENTS: In the U.S., durable goods orders for February rose 2.2%, versus expectations for a 3.0% increase. The core reading, which excludes transportation items, increased 1.6%, versus the expected increase of 1.7%... MARKET NEWS: Exxon Mobil (XOM), Shell (RDS.A), BP (BP), and Chevron (CVX) all declined as oil prices dropped following statements from France's energy minister about a possible joint oil reserve release coordinated between France, the U.S. and the U.K... Organic pasta maker Annie's (BNNY) soared after the company's initial public offering, which priced above its expected range at $19. The stock is up almost 72% to $32.63 near noon... MAJOR MOVERS: Among the notable gainers were Amylin (AMLN), after Bloomberg reported that the company rejected a $22 per share takeover offer from Bristol-Myers (BMY) earlier this year, and Pentair (PNR), after the company agreed to merge with Tyco's (TYC) Flow Control business to create a combined company that sees pro forma 2012 revenues of $7.7B. Noteworthy losers included SYNNEX (SNX), following a downgrade at Citigroup on the company's disappointing guidance for Q2, and Alimera (ALIM), after the company said last night that based on recent discussions with European regulatory authorities it thinks it will take longer than originally anticipated to obtain marketing authorizations for it ILUVIEN drug... INDICES: Near noon, the Dow was down 83.97, or 0.64%, to 13,113.76; the Nasdaq was down 24.20, or 0.78%, to 3,096.15; and the S&P 500 was down 11.26, or 0.80%, to 1,401.26.
News For A;CVX;BNNY;AMLN;BMY;PNR;TYC;SNX;ALIM From The Last 14 Days
Check below for free stories on A;CVX;BNNY;AMLN;BMY;PNR;TYC;SNX;ALIM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
12:50 EDTBMYEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
06:38 EDTCVXRising oil supplies pressuring prices, NY Times says
Subscribe for More Information
August 27, 2014
09:53 EDTBMYOn The Fly: Analyst Initiation Summary
Bristol-Myers (BMY) initiated with a Hold at Deutsche Bank... ASML (ASML) initiated with a Hold at Stifel... Akamai (AKAM) initiated with an Outperform at RW Baird... Concur (CNQR) initiated with a Neutral at DA Davidson... CyrusOne (CONE) initiated with a Neutral at Citigroup... Eli Lilly (LLY) initiated with a Buy at Deutsche Bank... Garmin (GRMN) initiated with a Neutral at RW Baird... Merck (MRK) initiated with a Hold at Deutsche Bank... NetSuite (N) initiated with a Buy at DA Davidson... Oracle (ORCL) initiated with a Neutral at DA Davidson... Oxford Industries (OXM) initiated with a Buy at Wunderlich... Pfizer (PFE) initiated with a Buy at Deutsche Bank... ServiceNow (NOW) initiated with a Buy at DA Davidson... Workday (WDAY) initiated with a Neutral at DA Davidson... MannKind (MNKD) initiated with a Buy at Jefferies... STMicroelectronics (STM) initiated with an Underperform at Credit Suisse... Kirkland's (KIRK) initiated with an Outperform at Barrington.
06:42 EDTBMYBristol-Myers initiated with a Hold at Deutsche Bank
Target $52.
05:44 EDTBMYBristol-Myers Daklinza approved by EC
Bristol-Myers announced that the European Commission, or EC, has approved Daklinza for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus, or HCV, infection in adults. Daklinza, when used in combination with sofosbuvir, is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials, including patients with advanced liver disease, genotype 3 and those who have previously failed treatment with protease inhibitors. Daklinza is the first NS5A complex inhibitor approved in the European Union and will be available for use in combination with other medicinal products, providing a shorter treatment duration compared to 48 weeks of treatment with interferon- and ribavirin-based regimens. The approval allows for the marketing of Daklinza in all 28 Member States of the EU. The marketing authorization for Daklinza follows an accelerated assessment by the Committee for Medicinal Products for Human Use, a designation that is granted to new medicines of major public health interest.
August 26, 2014
06:45 EDTCVXChevron aims for $1.5B in Canadian oil endeavor, Reuters says
Subscribe for More Information
August 25, 2014
16:36 EDTCVXPacific Drilling gets firm contract extension for the Pacific Bora
Subscribe for More Information
August 22, 2014
12:39 EDTBMYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
13:32 EDTBMYBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
August 20, 2014
08:03 EDTBMYBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 18, 2014
07:57 EDTBMYCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use